Tiotropium versus placebo for chronic obstructive pulmonary disease

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Clinical Trials

Background:

• Tiotropium is a widely accepted once-daily maintenance therapy for stable chronic obstructive pulmonary disease (COPD).
• Recent trials, including those with soft mist inhalers, necessitate an updated efficacy review of tiotropium versus placebo.

Purpose of the Study:

• To evaluate randomized controlled trials (RCTs) comparing tiotropium efficacy against placebo in COPD patients.
• Focus on clinically significant endpoints related to quality of life, exacerbations, and mortality.

Main Methods:

• Systematic search of Cochrane Airways Group's Register and ClinicalTrials.gov up to February 2012.
• Inclusion of parallel-group RCTs of at least three months duration comparing tiotropium with placebo in COPD patients.
• Independent data extraction, quality assessment, and analysis using Cochrane Review Manager software.

Main Results:

• 22 RCTs with 23,309 COPD participants were included.
• Tiotropium significantly improved quality of life (St George's Respiratory Questionnaire) and reduced exacerbations (NNT 16).
• Reduced hospitalizations due to exacerbations, but no significant difference in all-cause hospitalizations or mortality. Mortality risk differed between Handihaler and Respimat devices.

Conclusions:

• Tiotropium effectively improves quality of life and reduces exacerbations in stable COPD patients.
• It is a reasonable treatment option for COPD management as per guidelines.
• Inhaler device type may influence mortality risk, a finding requiring further investigation and consideration in clinical practice.